Possible involvement of copper(II) in Alzheimer disease

Environ Health Perspect. 2002 Oct;110 Suppl 5(Suppl 5):869-70. doi: 10.1289/ehp.02110s5869.

Abstract

The beta-amyloid (Abeta) peptide is a principal component of insoluble amyloid plaques that are characteristic neuropathological features of Alzheimer disease (AD). The amyloid peptide also exists as a normal soluble protein that undergoes a pathogenic transition to an aggregated, fibrous form. This transition can be affected by extraneous proteinaceous elements and nonproteinaceous elements such as copper ions, which may promote aggregation and/or stabilization of the fibrils. Copper has been found in abnormally high concentrations in amyloid plaques and AD-affected neuropil, and copper-selective chelators have been shown to dissolve Abeta peptide from postmortem brain specimens. Although Cu(2+) is an essential element for life and the function of numerous enzymes is basic to neurobiology, free or incorrectly bound Cu(2+) can also catalyze generation of the most damaging radicals, such as hydroxyl radical, giving a chemical modification of the protein, alternations in protein structure and solubility, and oxidative damage to surrounding tissue.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / physiopathology*
  • Amyloid beta-Peptides / drug effects*
  • Amyloid beta-Peptides / physiology
  • Brain / drug effects
  • Brain / pathology
  • Cell Aggregation
  • Chelating Agents
  • Copper / adverse effects*
  • Copper / chemistry
  • Humans
  • Hydroxyl Radical / adverse effects
  • Ions
  • Oxidative Stress
  • Peptide Fragments
  • Plaque, Amyloid / drug effects*
  • Risk Factors
  • Solubility

Substances

  • Amyloid beta-Peptides
  • Chelating Agents
  • Ions
  • Peptide Fragments
  • Hydroxyl Radical
  • Copper